{"id":"W2168063883","doi":"10.1093/annonc/mdt571","title":"Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":128,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"Janssen Pharmaceuticals; Amgen; Astellas Pharma; Association for Federal Information Resources Management","keywords":"Enzalutamide; Medicine; Prostate cancer; Hazard ratio; Placebo; Internal medicine; Population; Docetaxel; Adverse effect; Progression-free survival; Urology; Confidence interval; Oncology; Androgen receptor; Chemotherapy; Cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000679679,0.0004466972,0.0009362285,0.0001142809,0.0001861256,0.0004739311,0.0002287497,0.0003575911,0.0009221986],"category_scores_gemma":[0.0007120601,0.0001029312,0.0008176017,0.000227216,0.0002969342,0.0003374282,0.0002026284,0.0007893397,0.0001345022],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000411322,"about_ca_system_score_gemma":0.0004300523,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001225182,"about_ca_topic_score_gemma":0.004398179,"domain_scores_codex":[0.9998465,0.00006830842,0.00001091532,0.00002135102,0.0000197534,0.00003315014],"domain_scores_gemma":[0.9997039,0.00005903536,0.0001070592,0.00001446169,0.00001796063,0.00009749562],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6037139,0.006183126,0.1275719,0.001319232,0.007041177,0.0004666858,0.0002689394,0.002685023,0.01367861,0.0004398061,0.009593382,0.2270383],"study_design_scores_gemma":[0.2390028,0.1230211,0.6081313,0.0002960028,0.008716892,0.001066769,0.0004009959,0.00245634,0.00256568,0.001238661,0.01300018,0.0001033447],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9909793,0.006998684,0.00006752949,0.0004983966,0.00008258939,0.0000390304,0.000307372,0.00001459271,0.001012581],"genre_scores_gemma":[0.9939786,0.0037395,0.0001749815,0.0006565048,0.0001837389,0.0000424662,0.0006689787,0.000004568966,0.000550464],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001225182,"threshold_uncertainty_score":0.003594518,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0580529218207753,"score_gpt":0.3790785064417077,"score_spread":0.3210255846209324,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}